Peter Caputo, MD
Urology · Holladay, UTNPI 1992050041
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.3%), education and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Intuitive Surgical at 53.5% of the total. 2025 is the largest year on record at $4,513, 8.1 times the $560 reported in 2019.
Across 141 payments — averaging $50.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AbbVie$463
- Boston Scientific$363
- Calyxo, Inc.$353
- Astellas Pharma US Inc$279
- Pfizer$210
- plus $2K from 32 others
What the payments were for
- Travel & lodging$6549%
- Food & beverage$3,41548%
- Education$3,00042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $3,785 |
| AbbVie(2 entities) | 24 | $463 |
| Boston Scientific | 10 | $363 |
| Calyxo, Inc. | 5 | $353 |
| Astellas Pharma US Inc | 15 | $279 |
| Pfizer | 11 | $210 |
| Procept Biorobotics Corporation | 5 | $200 |
| Laborie Medical Technologies Corp. | 2 | $166 |
| Ferring Pharmaceuticals Inc. | 3 | $164 |
| Travere Therapeutics, Inc. | 5 | $114 |
| Merck | 4 | $75 |
| Amgen | 3 | $67 |
| Myovant Sciences Inc. | 4 | $60 |
| Urovant Sciences Inc | 3 | $59 |
| Urogen Pharma, Inc. | 2 | $57 |
| Janssen Scientific Affairs, LLC | 2 | $53 |
| Antares Pharma, Inc. | 3 | $50 |
| Blue Earth Diagnostics | 2 | $47 |
| Johnson & Johnson(2 entities) | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Myriad Genetic Laboratories, Inc. | 3 | $37 |
| Bayer | 2 | $30 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Angiodynamics, Inc. | 1 | $28 |
| Dendreon Pharmaceuticals LLC | 1 | $26 |
| Novartis | 1 | $23 |
| Axonics, Inc. | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Neotract Inc. | 1 | $20 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $18 |
| Smith+Nephew | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Photocure Inc | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$3,000
- Da Vinci Surgical System$498
- CVAC Aspiration System$173
- AquaBeam Robotic System$120
- NOCDURNA$112
How this compares
$7,069 in reported general payments places this provider in the 65th percentile of 96 urology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 52 | $46,005 |
| Finasteride | 298 | $3,990 |
| Tamsulosin Hcl | 224 | $2,916 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,574 |
| Testosterone Cypionate | 22 | $1,129 |
| Methenamine Hippurate | 21 | $901 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 19 | $382 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 14 | $264 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 69 | $206 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $158 |
| Ibuprofen | 25 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $279 | $46,00552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 96 urology providers in Utah.
Other urology in Holladay
- Steven GangeSlc$1.5M
- William BrantSalt Lake City$290K
- Roscoe NelsonAmerican Fork$152K
- Nathan PursifullAmerican Fork$86K
- Benjamin McCormickSalt Lake City$67K
- Richard MaternSalt Lake City$58K
- Akhil SajiSalt Lake City$49K
- Jeffrey SparenborgProvo$37K
- Daniel SimonRiverton$33K
- Stewart LandauAmerican Fork$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.